Louisiana Patient Marks First Regional Functional Cure of Sickle Cell via Casgevy CRISPR Therapy

Cressy’s treatment followed the standard Casgevy protocol of autologous CD34+ cell collection, CRISPR-Cas9 editing to disrupt the BCL11A enhancer, myeloablative busulfan conditioning, and reinfusion. Post-infusion data showed sustained fetal hemoglobin elevation above 30% with elimination of vaso-occlusive crises, matching the 94% crisis-free rate at 12 months in the pivotal CLIMB-131 trial reported in the New England Journal of Medicine. Regional first status underscores how insurance navigation and center expertise still gatekeep access despite FDA approval in December 2023.

Casgevy’s list price of $2.2 million plus ancillary costs creates documented coverage delays, as Cressy experienced. Observational data from the CDC’s Sickle Cell Data Collection program indicate Black Americans face 3.5-fold higher hospitalization rates yet lower referral rates to gene-therapy centers, amplifying geographic disparities beyond the clinical milestone itself.

Next steps require state Medicaid policy reforms and expanded qualified treatment centers; without these, the therapy will remain concentrated in a handful of academic hubs rather than scaling to the estimated 100,000 U.S. patients eligible under current labeling.